InFocus Partners’ Investment to Accelerate Development of Pr3vent's Breakthrough Artificial Intelligence Eye Screening Tool for Newborns PALO ALTO, Calif., February 12, 2019-- Pr3vent, Inc., a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners, a venture capital fund specializing in the identification, capitalization and development of breakthrough and disruptive opportunities in the ophthalmic space. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Trousdale Ventures.